Literature DB >> 11008044

Long-term results of the foldable CeeOn Edge intraocular lens.

W H Schmack1, K Gerstmeyer.   

Abstract

PURPOSE: To determine the long-term efficacy and safety of the foldable silicone CeeOn Edge(R) model 911 intraocular lens (IOL).
SETTING: Eye Clinic, Klinikum Minden, Germany.
METHODS: A high-refractive-index silicone lens with a sharp edge was implanted after phacoemulsification in 42 eyes of 36 patients. Best corrected visual acuity (BCVA) and occurrence of complications were evaluated during a 3 year follow-up.
RESULTS: No significant postoperative complications were seen. At 3 years, 26 eyes of 22 patients were available for examination. The BCVA was 0.5 (20/40) or better in 92% of eyes and 1.0 (20/20) or better in 39%. No posterior capsule opacification (PCO) was observed, and neodymium:YAG capsulotomy was not indicated in any patient.
CONCLUSIONS: This pilot study indicates that the performance and safety of the foldable silicone CeeOn Edge lens are excellent. The results support the theory that a sharp edge on the IOL prevents the development of PCO.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008044     DOI: 10.1016/s0886-3350(00)00522-8

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  4 in total

1.  [Influence of intraocular lens material and design on the development of posterior capsule opacification].

Authors:  O Nishi
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

2.  [Accuracy of lens power calculation and centration of an aspheric intraocular lens].

Authors:  K A Becker; M P Holzer; A J Reuland; G U Auffarth
Journal:  Ophthalmologe       Date:  2006-10       Impact factor: 1.059

3.  Comparison of outcomes with multifocal intraocular lenses: a meta-analysis.

Authors:  Béatrice Cochener; Antoine Lafuma; Babak Khoshnood; Laurène Courouve; Gilles Berdeaux
Journal:  Clin Ophthalmol       Date:  2011-01-07

4.  Modelling lifetime cost consequences of ReSTOR in cataract surgery in four European countries.

Authors:  Antoine Lafuma; Gilles Berdeaux
Journal:  BMC Ophthalmol       Date:  2008-07-15       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.